These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 23286294)

  • 41. Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk.
    Woodruff T
    Intern Med J; 2006 Dec; 36(12):797-8; author reply 798-9. PubMed ID: 17096747
    [No Abstract]   [Full Text] [Related]  

  • 42. [The safety of COX-2 inhibitors].
    Lakatos G; Herszényi L; Tulassay Z
    Orv Hetil; 2008 Aug; 149(33):1539-47. PubMed ID: 18687572
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding.
    Konstantinopoulos PA; Lehmann DF
    J Clin Pharmacol; 2005 Jul; 45(7):742-50. PubMed ID: 15951464
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cyclooxygenase-2 inhibitors: what went wrong?
    James MJ; Cleland LG
    Curr Opin Clin Nutr Metab Care; 2006 Mar; 9(2):89-94. PubMed ID: 16477171
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract.
    Sostres C; Gargallo CJ; Arroyo MT; Lanas A
    Best Pract Res Clin Gastroenterol; 2010 Apr; 24(2):121-32. PubMed ID: 20227026
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The comparative safety of analgesics in older adults with arthritis.
    Solomon DH; Rassen JA; Glynn RJ; Lee J; Levin R; Schneeweiss S
    Arch Intern Med; 2010 Dec; 170(22):1968-76. PubMed ID: 21149752
    [TBL] [Abstract][Full Text] [Related]  

  • 47. FDA labeling of NSAIDs: Review of nonsteroidal anti-inflammatory drugs in cardiovascular disease.
    Pirlamarla P; Bond RM
    Trends Cardiovasc Med; 2016 Nov; 26(8):675-680. PubMed ID: 27238053
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Appropriate use of NSAIDs: considering cardiovascular risk in the elderly.
    Stillman MJ; Stillman MT
    Geriatrics; 2007 Mar; 62(3):16-21. PubMed ID: 17346094
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective.
    Patrono C
    Br J Clin Pharmacol; 2016 Oct; 82(4):957-64. PubMed ID: 27317138
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance.
    Borer JS; Simon LS
    Arthritis Res Ther; 2005; 7 Suppl 4(Suppl 4):S14-22. PubMed ID: 16168077
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Valat JP; Deray G; Héloire F
    Presse Med; 2006 Sep; 35(9 Spec No 1):1S25-34. PubMed ID: 17078592
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of traditional therapies and biologics on cardiovascular diseases in rheumatoid arthritis.
    Boyer JF; Cantagrel A; Constantin A
    Curr Vasc Pharmacol; 2008 Jul; 6(3):218-27. PubMed ID: 18673161
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 4 years after withdrawal of rofecoxib: where do we stand today?
    Jaksch W; Dejaco C; Schirmer M
    Rheumatol Int; 2008 Oct; 28(12):1187-95. PubMed ID: 18663451
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The murky waters of the coxibs: a review of the current state of play.
    Ostor AJ; Hazleman BL
    Inflammopharmacology; 2005; 13(4):371-80. PubMed ID: 16354390
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Coxibs: is there a benefit when compared to traditional non-selective NSAIDs in postoperative pain management?
    Wickerts L; Warrén Stomberg M; Brattwall M; Jakobsson J
    Minerva Anestesiol; 2011 Nov; 77(11):1084-98. PubMed ID: 21617597
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Cardiovascular risk of non-steroidal anti-inflammatory drugs].
    Prozzi GR; Cañás M; Urtasun MA; Buschiazzo HO; Dorati CM; Mordujovich-Buschiazzo P
    Medicina (B Aires); 2018; 78(5):349-355. PubMed ID: 30285927
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cardiovascular hazard of selective COX-2 inhibitors: myth or reality?
    Chiolero A; Maillard MP; Burnier M
    Expert Opin Drug Saf; 2002 May; 1(1):45-52. PubMed ID: 12904159
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardiovascular risks of cyclooxygenase inhibition.
    Stacy ZA; Dobesh PP; Trujillo TC
    Pharmacotherapy; 2006 Jul; 26(7):919-38. PubMed ID: 16803424
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical Pharmacology and Cardiovascular Safety of Naproxen.
    Angiolillo DJ; Weisman SM
    Am J Cardiovasc Drugs; 2017 Apr; 17(2):97-107. PubMed ID: 27826802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.